Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 21, 2009Journal of the American Society of NephrologyOpen Access

Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients

View Full Paper
Ask AI
Bookmark
Share

Authors

DADaniel AbramowiczUniversity of AntwerpDDD. DurandUniversité Libre de BruxellesGMGeorges MouradCentre Hospitalier Universitaire de Montpellier

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Abramowicz et al. (2009) studied this question.

synapsesocial.com/papers/6a9d5ed5605877da248b06f1https://doi.org/10.1681/asn.2008101037
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation2008 · 693 citations
  2. 2The Effect of Antilymphocyte Induction Therapy on Renal Allograft Survival1998 · 129 citations
  3. 3Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus Tacrolimus2007 · 612 citations
  4. 4HLA Mismatches Remain Risk Factors for Acute Kidney Allograft Rejection in Patients Receiving Quadruple Immunosuppression With Anti-Interleukin-2 Receptor Antibodies2008 · 48 citations
  5. 5A Comparison of Plasmapheresis Versus High-Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific Alloantibody2006 · 432 citations